Company news

Halozyme Therapeutics, Inc. (NASDAQ:HALO) news

Halozyme Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx…

Halozyme Therapeutics, Inc. (NASDAQ:HALO) news

Press releases & updates

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

Halozyme Announces Appointment of Jim Daly to its Board of Directors

Halozyme Announces Appointment of Jim Daly to its Board of Directors

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

Halozyme Appoints Dannielle Appelhans to its Board of Directors

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Appoints David Ramsay as President Drug Delivery

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme to Report First Quarter 2026 Financial and Operating Results

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Russell Investments Expands Canadian ETF Lineup With Five New Offerings

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Halozyme to Participate at Upcoming Investor Conferences

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications